---
layout: post
title: New Drug Approvals 2013 - Pt. XIX - Ibrutinib (ImbruvicaTM)
date: '2013-11-15T07:18:00.000Z'
author: Bissan Al-Lazikani
tags:
- Cancer
- 2013 New Drugs
modified_time: '2013-11-15T09:28:08.566Z'
thumbnail: http://3.bp.blogspot.com/-xezCpReT-BI/UoW3Cy1Uu_I/AAAAAAAAAPA/X2AZC6GB-YY/s72-c/imbruvica.jpg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-6746195892645998978
blogger_orig_url: http://chembl.blogspot.com/2013/11/new-drug-approvals-2013-pt-xix.html
---

<center>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://3.bp.blogspot.com/-xezCpReT-BI/UoW3Cy1Uu_I/AAAAAAAAAPA/X2AZC6GB-YY/s1600/imbruvica.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://3.bp.blogspot.com/-xezCpReT-BI/UoW3Cy1Uu_I/AAAAAAAAAPA/X2AZC6GB-YY/s200/imbruvica.jpg" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<img src="https://www.ebi.ac.uk/chembltools/autoiconlarge2/1,1,1,1,0,1,0,0,0,1" width="400" /><br />
<b><br /></b></center>
<center>
<b>ATC Code:</b></center>
<center>
<b>Wikipedia: </b><a href="http://en.wikipedia.org/wiki/Ibrutinib">Ibrutinib</a></center>
<br />
On November 13, 2013, the FDA approved Ibrutinib (Imbruvica<sup>TM</sup>) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. MCL is a subtype of B-cell lymphoma and accounts for 6% of non-Hodgkin's lymphoma cases. In an open-label, multi-center, single-arm trial of 111 previously treated patients, Ibrutinib showed a 65.8% response rate.<br />
<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://3.bp.blogspot.com/-5Zp2rZsfLZI/UoW4N7iX2mI/AAAAAAAAAPM/Ix_uD1OSdyc/s1600/BTK.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://3.bp.blogspot.com/-5Zp2rZsfLZI/UoW4N7iX2mI/AAAAAAAAAPM/Ix_uD1OSdyc/s200/BTK.png" /></a></div>
Ibrutinib is an irreversible inhibitor of the Tyrosine-protein kinase BTK (Uniprot:Q06187; ChEMBL:<a href="https://www.ebi.ac.uk/chembl/target/inspect/CHEMBL5251">CHEMBL5251</a>; <a href="https://cansar.icr.ac.uk/cansar/molecular-targets/Q06187/">canSAR target synopsis</a>) and is the first approved targeted BTK inhibitor. It forms a covalent bond with a cysteine residue <i>via</i> a Michael acceptor mechanism, in the BTK active site, leading to inhibition of BTK enzymatic activity<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-WtdeSwR3Tm0/UoW4a7qkhaI/AAAAAAAAAPc/AqMnQYjJsoY/s1600/Ibrutinib.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://2.bp.blogspot.com/-WtdeSwR3Tm0/UoW4a7qkhaI/AAAAAAAAAPc/AqMnQYjJsoY/s320/Ibrutinib.png" /></a></div>
<br />
Ibrutinib (ChEMBL:<a href="https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1873475">CHEMBL1873475</a>; <a href="https://cansar.icr.ac.uk/cansar/compounds/1010435/">canSAR drug synopsis</a>; also known as CRA-032765 and PCI-32765) has the formula C25H24N6O2 and a molecular weight 440.50. It is absorbed after oral administration with a median Tmax of 1-2 hours. After administration of 560 mg dose, the observed AUC is 953 ± 705 ng⋅h/mL. The apparent volume of distribution at steady state (Vd,ss/F) is approximately 10000 L and the half-life is 4 to 6 hours.<br />
<br />
Imbruvica<sup>TM</sup> is produced by <a href="http://ir.pharmacyclics.com/releasedetail.cfm?ReleaseID=807003">Pharmacyclics, Inc.</a><br />
<br />
The full Prescribing Information is <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205552lbl.pdf">here</a>